RESULT OF GENERAL MEETING AND DIRECTORS DEALING

RNS Number : 7066J

Oxford Biomedica PLC

16 June 2014

 



FOR IMMEDIATE RELEASE

16 June 2014

OXFORD BIOMEDICA PLC

RESULT OF GENERAL MEETING AND DIRECTORS DEALING

Oxford, UK - 16 June 2014: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its General Meeting, held today in London.

In accordance with Listing Rule 9.6.18, the following resolution passed at the meeting concerned special business:

·      Resolution 2: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of £12,832,486.16.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 134 to 136 of the prospectus dated 29 May 2014).

Certified copies of the document setting out the above resolutions passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolution
1	677,773,077	995,046	11,700	569,956	18,474	679,368,253	Passed
Special resolution
2	677,820,393	589,675	11,700	309,110	637,375	679,368,253	Passed
Ordinary resolution
3	313,817,070	689,296	11,700	664,606	185,581	315,368,253	Passed

In addition, following the proposed fundraising announced on 29 May 2014, the table below details the Number of Ordinary Shares now beneficially held by the Directors and their connected persons in the share capital of the Company:

Name of Director	Title	Number of Ordinary Shares Purchased	Number of Ordinary Shares beneficially held immediately following Admission	Percentage of issued ordinary shares beneficially held immediately following Admission
Nick Rodgers	Non-Executive Chairman	200,000	1,042,829	0.04%
John Dawson	Chief Executive Officer	500,000	2,782,829	0.11%
Peter Nolan	Senior Vice President, Commercial Development	150,000	883,313	0.04%
Tim Watts	Chief Financial Officer	1,625,000	5,307,829	0.21%
Dr. Paul Blake	Non-Executive Director	1,250,000	1,783,097	0.07%
Dr. Andrew Heath	Non-Executive Director	250,000	850,000	0.03%
Martin Diggle 1	Non-Executive Director	132,250,000	533,250,100 2	21.38% 2

(1)  Includes interests of Vulpes Life Sciences Fund and other parties connected to Martin Diggle

(2)  Includes the Related Party Subscription

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes to editors

Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

MSCZMGMVMVRGDZM